Regulatory – Page 14 – Alligator Bioscience

2017-07-21

Regulatory

Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

Strategic partnership will advance development of a novel bispecific immuno-oncology antibody targeting compelling biological pathway implic ...

2017-06-12

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX), a biotechnology company developing antibody-based pharmaceuticals for canc ...

2017-05-04

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today presented new pre-clinical data on the CD40 agonistic immuno-oncology ...

2017-05-02

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announced its report for the first quarter 2017. “In the first quarte ...

2017-03-31

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that the number of shares and votes in Alligator Bios ...

2017-03-23

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that the first phase I study with ADC-1013, a human, ...

2017-03-222022-09-20

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announces that that the Swedish version of Annual Report for 20 ...

2017-02-17

Regulatory

Summary During the quarter were the company’s shares listed for trading on Nasdaq Stockholm Mid Cap. In connection with this were new shares ...

2017-01-31

Regulatory

During December, the number of shares and votes in Alligator Bioscience AB (publ) has increased due to that 700,000 warrants in the warrant ...